Biomarkers for Wilms Tumor: A Systematic Review

Eugene B. Cone, Stewart S. Dalton, Megan Van Noord, Elizabeth T. Tracy, Henry E. Rice, Jonathan C. Routh

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers. Materials and Methods We searched for English language studies from 1980 to 2015 performed in patients younger than 18 years with Wilms tumor and prognostic data. The protocol was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two reviewers abstracted data in duplicate using a standard evaluation form. We performed descriptive statistics, then calculated relative risks and 95% confidence intervals for markers appearing in multiple level II or III studies. Results A total of 40 studies were included examining 32 biomarkers in 7,381 patients with Wilms tumor. Studies had a median of 61 patients, 24 biomarker positive patients per series and a median followup of 68.4 months. Median percentages of patients with stages 1, 2, 3, 4 and 5 tumors were 28.5%, 26.4%, 24.5%, 14.1% and 1.7%, respectively, and 10.2% had anaplasia. The strongest negative prognostic association was loss of heterozygosity at 11p15, with a risk of recurrence of 5.00, although loss of heterozygosity at 1p and gain of function at 1q were also strongly linked to increased recurrence (2.93 and 2.86, respectively). Conclusions Several tumor markers are associated with an increased risk of recurrence or a decreased risk of overall survival in patients with Wilms tumor. These data suggest targets for development of diagnostic tests and potential therapies.

Original languageEnglish (US)
Pages (from-to)1530-1535
Number of pages6
JournalJournal of Urology
Volume196
Issue number5
DOIs
StatePublished - Nov 1 2016
Externally publishedYes

Fingerprint

Wilms Tumor
Biomarkers
Loss of Heterozygosity
Tumor Biomarkers
Recurrence
Anaplasia
Neoplasms
Routine Diagnostic Tests
Meta-Analysis
Language
Guidelines
Confidence Intervals
Kidney
Survival

Keywords

  • biomarkers
  • kidney neoplasms
  • pediatrics
  • prognosis
  • Wilms tumor

ASJC Scopus subject areas

  • Urology

Cite this

Cone, E. B., Dalton, S. S., Van Noord, M., Tracy, E. T., Rice, H. E., & Routh, J. C. (2016). Biomarkers for Wilms Tumor: A Systematic Review. Journal of Urology, 196(5), 1530-1535. https://doi.org/10.1016/j.juro.2016.05.100

Biomarkers for Wilms Tumor : A Systematic Review. / Cone, Eugene B.; Dalton, Stewart S.; Van Noord, Megan; Tracy, Elizabeth T.; Rice, Henry E.; Routh, Jonathan C.

In: Journal of Urology, Vol. 196, No. 5, 01.11.2016, p. 1530-1535.

Research output: Contribution to journalArticle

Cone, EB, Dalton, SS, Van Noord, M, Tracy, ET, Rice, HE & Routh, JC 2016, 'Biomarkers for Wilms Tumor: A Systematic Review', Journal of Urology, vol. 196, no. 5, pp. 1530-1535. https://doi.org/10.1016/j.juro.2016.05.100
Cone EB, Dalton SS, Van Noord M, Tracy ET, Rice HE, Routh JC. Biomarkers for Wilms Tumor: A Systematic Review. Journal of Urology. 2016 Nov 1;196(5):1530-1535. https://doi.org/10.1016/j.juro.2016.05.100
Cone, Eugene B. ; Dalton, Stewart S. ; Van Noord, Megan ; Tracy, Elizabeth T. ; Rice, Henry E. ; Routh, Jonathan C. / Biomarkers for Wilms Tumor : A Systematic Review. In: Journal of Urology. 2016 ; Vol. 196, No. 5. pp. 1530-1535.
@article{ba0a64c8d3be4542b6fbc2e1e4ddfc6b,
title = "Biomarkers for Wilms Tumor: A Systematic Review",
abstract = "Purpose Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers. Materials and Methods We searched for English language studies from 1980 to 2015 performed in patients younger than 18 years with Wilms tumor and prognostic data. The protocol was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two reviewers abstracted data in duplicate using a standard evaluation form. We performed descriptive statistics, then calculated relative risks and 95{\%} confidence intervals for markers appearing in multiple level II or III studies. Results A total of 40 studies were included examining 32 biomarkers in 7,381 patients with Wilms tumor. Studies had a median of 61 patients, 24 biomarker positive patients per series and a median followup of 68.4 months. Median percentages of patients with stages 1, 2, 3, 4 and 5 tumors were 28.5{\%}, 26.4{\%}, 24.5{\%}, 14.1{\%} and 1.7{\%}, respectively, and 10.2{\%} had anaplasia. The strongest negative prognostic association was loss of heterozygosity at 11p15, with a risk of recurrence of 5.00, although loss of heterozygosity at 1p and gain of function at 1q were also strongly linked to increased recurrence (2.93 and 2.86, respectively). Conclusions Several tumor markers are associated with an increased risk of recurrence or a decreased risk of overall survival in patients with Wilms tumor. These data suggest targets for development of diagnostic tests and potential therapies.",
keywords = "biomarkers, kidney neoplasms, pediatrics, prognosis, Wilms tumor",
author = "Cone, {Eugene B.} and Dalton, {Stewart S.} and {Van Noord}, Megan and Tracy, {Elizabeth T.} and Rice, {Henry E.} and Routh, {Jonathan C.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.juro.2016.05.100",
language = "English (US)",
volume = "196",
pages = "1530--1535",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Biomarkers for Wilms Tumor

T2 - A Systematic Review

AU - Cone, Eugene B.

AU - Dalton, Stewart S.

AU - Van Noord, Megan

AU - Tracy, Elizabeth T.

AU - Rice, Henry E.

AU - Routh, Jonathan C.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Purpose Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers. Materials and Methods We searched for English language studies from 1980 to 2015 performed in patients younger than 18 years with Wilms tumor and prognostic data. The protocol was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two reviewers abstracted data in duplicate using a standard evaluation form. We performed descriptive statistics, then calculated relative risks and 95% confidence intervals for markers appearing in multiple level II or III studies. Results A total of 40 studies were included examining 32 biomarkers in 7,381 patients with Wilms tumor. Studies had a median of 61 patients, 24 biomarker positive patients per series and a median followup of 68.4 months. Median percentages of patients with stages 1, 2, 3, 4 and 5 tumors were 28.5%, 26.4%, 24.5%, 14.1% and 1.7%, respectively, and 10.2% had anaplasia. The strongest negative prognostic association was loss of heterozygosity at 11p15, with a risk of recurrence of 5.00, although loss of heterozygosity at 1p and gain of function at 1q were also strongly linked to increased recurrence (2.93 and 2.86, respectively). Conclusions Several tumor markers are associated with an increased risk of recurrence or a decreased risk of overall survival in patients with Wilms tumor. These data suggest targets for development of diagnostic tests and potential therapies.

AB - Purpose Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers. Materials and Methods We searched for English language studies from 1980 to 2015 performed in patients younger than 18 years with Wilms tumor and prognostic data. The protocol was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two reviewers abstracted data in duplicate using a standard evaluation form. We performed descriptive statistics, then calculated relative risks and 95% confidence intervals for markers appearing in multiple level II or III studies. Results A total of 40 studies were included examining 32 biomarkers in 7,381 patients with Wilms tumor. Studies had a median of 61 patients, 24 biomarker positive patients per series and a median followup of 68.4 months. Median percentages of patients with stages 1, 2, 3, 4 and 5 tumors were 28.5%, 26.4%, 24.5%, 14.1% and 1.7%, respectively, and 10.2% had anaplasia. The strongest negative prognostic association was loss of heterozygosity at 11p15, with a risk of recurrence of 5.00, although loss of heterozygosity at 1p and gain of function at 1q were also strongly linked to increased recurrence (2.93 and 2.86, respectively). Conclusions Several tumor markers are associated with an increased risk of recurrence or a decreased risk of overall survival in patients with Wilms tumor. These data suggest targets for development of diagnostic tests and potential therapies.

KW - biomarkers

KW - kidney neoplasms

KW - pediatrics

KW - prognosis

KW - Wilms tumor

UR - http://www.scopus.com/inward/record.url?scp=84992390903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992390903&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2016.05.100

DO - 10.1016/j.juro.2016.05.100

M3 - Article

C2 - 27259655

AN - SCOPUS:84992390903

VL - 196

SP - 1530

EP - 1535

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -